ProCE Banner Activity

MajesTEC-1: Update From Phase I/II Trial of the BCMA x CD3 Bispecific Antibody Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Teclistamab was associated with a high response rate and durable responses in patients with highly refractory MM not previously treated with BCMA-targeted therapy.

Released: June 07, 2022

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

BMS

Daiichi Sankyo Inc

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab